Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 13;59(1):2100917.
doi: 10.1183/13993003.00917-2021. Print 2022 Jan.

R-scale for pulmonary fibrosis: a simple, visual tool for the assessment of health-related quality of life

Affiliations
Free article

R-scale for pulmonary fibrosis: a simple, visual tool for the assessment of health-related quality of life

Ciaran Scallan et al. Eur Respir J. .
Free article

Abstract

Rationale: Patients with idiopathic pulmonary fibrosis (IPF) experience impaired health-related quality of life (HRQoL). Several tools have been developed to objectively assess HRQoL in this patient population, but none are in use in routine clinical practice.

Objectives: To develop a rapid, specific tool that can be used for patients with IPF during routine clinic visits.

Methods: A novel and simple five-item numerical rating scale was developed and compared with two other previously validated tools. 100 consecutive patients with IPF managed at a centre for interstitial lung disease were recruited to complete the Raghu scale for pulmonary fibrosis (R-Scale-PF), King's Brief Interstitial Lung Disease questionnaire (K-BILD), and the EuroQol Five-Dimensional Five-Level questionnaire (EQ-5D-5L) in addition to pulmonary function and 6-min walk tests.

Measurements and main results: All 100 patients successfully completed the three HRQoL tools with 53 completing them again at follow-up visits. Internal consistency was high (Cronbach's α 0.825) with minimal floor/ceiling effect. Concurrent validity of the R-Scale-PF was moderate to high compared with the K-BILD (r=-0.713) and the EQ-5D-5L (r=-0.665). Concurrent validity was moderate with physiologic measures (forced vital capacity, r=-0.307, 6-min walking distance, r=-0.383). The R-Scale-PF demonstrated good known-groups validity when comparing scores across stages of disease severity.

Conclusions: The R-Scale-PF correlates well with the K-BILD and EQ-5D-5L. It is hoped that this novel simple numerical rating scale tool, subject to validation in patients from other centres, will provide an opportunity to objectively measure HRQoL in routine clinical practice for patients with IPF.

Trial registration: ClinicalTrials.gov NCT04148157.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: C. Scallan has nothing to disclose. Conflict of interest: L. Strand has nothing to disclose. Conflict of interest: J. Hayes has nothing to disclose. Conflict of interest: S. Kadura has nothing to disclose. Conflict of interest: B. Collins reports personal fees for advisory board work from Boehringer Ingelheim, outside the submitted work. Conflict of interest: L. Ho has nothing to disclose. Conflict of interest: C. Spada has nothing to disclose. Conflict of interest: W. Canestaro has nothing to disclose. Conflict of interest: M. Kolb reports grants from Canadian Pulmonary Fibrosis Foundation and Canadian Institute for Health Research, other (site PI in industry-sponsored clinical trials) from Roche, grants, personal fees for advisory board work and other (site PI in industry-sponsored clinical trials) from Boehringer Ingelheim, grants and personal fees for advisory board work from Roche, Liminal and Pieris, other (chief editor allowance) from European Respiratory Journal, personal fees for advisory board work from Third Pole, MitoImmune, Abbvie, DevPro Biopharma, Horizon, Algernon and CSL Behring, outside the submitted work. Conflict of interest: G. Raghu has nothing to disclose.

Comment in

Similar articles

Cited by

Associated data

LinkOut - more resources